Search
Valspodar
go.drugbank.com/drugs/DB11869InvestigationalValspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the tr...
Categories: P-glycoprotein inducers, Cytochrome P-450 Substrates6-O-benzylguanine
go.drugbank.com/drugs/DB11919Investigational6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSelinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed fro...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalDacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain o...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSJG-136
go.drugbank.com/drugs/DB11965InvestigationalSJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes,...
Categories: P-glycoprotein substratesBinimetinib
go.drugbank.com/drugs/DB11967ApprovedInvestigationalBinimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib. On June 27, 2018, the Food and Drug Administration approved the combination o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesPonesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-ph...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLorvotuzumab mertansine
go.drugbank.com/drugs/DB12089InvestigationalLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSecoisolariciresinol
go.drugbank.com/drugs/DB12179InvestigationalSecoisolariciresinol has been used in trials studying the prevention of Breast Cancer.
Categories: P-glycoprotein inhibitors